Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DEI4U0
|
|||
| Drug Name |
HMR59
|
|||
| Synonyms |
AAVCAGsCD59
Click to Show/Hide
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Dry age-related macular degeneration [ICD-11: 9B75; ICD-10: H35.31] | Phase 2 | [1] | |
| Geographic retinal atrophy [ICD-11: 9B78.9] | Phase 2 | [1] | ||
| Wet age-related macular degeneration [ICD-11: 9B78.3Z; ICD-10: H35.31] | Phase 2 | [1] | ||
| Company |
Hemera Biosciences
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Membrane inhibitor of reactive lysis (CD59) | Target Info | Replacement | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04358471) Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Hemera Biosciences. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.